Literature DB >> 16908

Human thrombins. Production, evaluation, and properties of alpha-thrombin.

J W Fenton, M J Fasco, A B Stackrow.   

Abstract

Human alpha-thrombin, the thromboplastin activation product of prothrombin with high clotting and esterase activity, was produced from Cohn Fraction III paste. The procedure started with 0.4 to 3.2 kg of frozen paste and was completed in 2 or 3 days. Some 23 g of thrombin were recorded for 65 quantitated preparations made from 11 lots of Fraction III paste. These preparations were obtained at protein concentrations of 3.9 +/- 1.3 mg/ml with a yield of 340 +/- 110 mg/kg of paste, which represented 48 +/- 14% of the clotting potential extracted as prothrombin. They had specific clotting activities of 2.8 +/- 0.4 U.S. (NIH) units/microng of protein and titrated to 88 +/- 8% active with p-nitrophenyl-p'-guanidinobenzoate (NPGB). Those (N - 29) examined by labeling with [14C]diisopropyl phosphorofluoridate (iPr2P-F) and electrophoresing in sodium dodecyl sulfate (SDS)-polyacrylamide gels were found to contain only (N = 4) or predominantly alpha-thrombin (97 +/- 3%) and corresponding amounts of ists degradation product, beta-thrombin (2.6 +/- 3.1%). No plasmin(ogen), prothrombin complex factors (II, VII, IX, IXalpha, X, Xalpha), or prothrombin fragments were detected in representative preparations. As produced in 0.75 M NaCl, pH approximately 6, thrombin was stable for approximately 1 week at 4 degrees and for greater than 1 year at less than or equal to 50 degrees; freeze-dried thrombin stored at 4 degrees for greater than 1 year displayed stable clotting activity and no vial to vial variation, permitting its use for reference purposes. Human thrombin generated by Taipan snake venom activation was compared with that produced by rapid thromboplastin activation: after treatment with [14C]iPr2P-F, greater than 95% of the label in both thrombins migrated at the same rate during electrophoresis in SDS; identical pairs of NH2-terminal residues were released in three consecutive Edman degradation cycles.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 16908

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  100 in total

1.  Activation of factor V during intrinsic and extrinsic coagulation. Inhibition by heparin, hirudin and D-Phe-Pro-Arg-Ch2Cl.

Authors:  X J Yang; M A Blajchman; S Craven; L M Smith; N Anvari; F A Ofosu
Journal:  Biochem J       Date:  1990-12-01       Impact factor: 3.857

2.  "Mirror image" antagonists of thrombin-induced platelet activation based on thrombin receptor structure.

Authors:  D T Hung; T K Vu; V I Wheaton; I F Charo; N A Nelken; N Esmon; C T Esmon; S R Coughlin
Journal:  J Clin Invest       Date:  1992-02       Impact factor: 14.808

3.  Anti-thrombin activities of heparin. Effect of saccharide chain length on thrombin inhibition by heparin cofactor II and by antithrombin.

Authors:  B Bray; D A Lane; J M Freyssinet; G Pejler; U Lindahl
Journal:  Biochem J       Date:  1989-08-15       Impact factor: 3.857

4.  Inhibition of the amplification reactions of blood coagulation by site-specific inhibitors of alpha-thrombin.

Authors:  F A Ofosu; J W Fenton; J Maraganore; M A Blajchman; X Yang; L Smith; N Anvari; M R Buchanan; J Hirsh
Journal:  Biochem J       Date:  1992-05-01       Impact factor: 3.857

5.  Effect of Na+ binding on the conformation, stability and molecular recognition properties of thrombin.

Authors:  Vincenzo De Filippis; Elisa De Dea; Filippo Lucatello; Roberta Frasson
Journal:  Biochem J       Date:  2005-09-01       Impact factor: 3.857

6.  Active release of human platelet factor VIII-related antigen by adenosine diphosphate, collagen, and thrombin.

Authors:  J Koutts; P N Walsh; E F Plow; J W Fenton; B N Bouma; T S Zimmerman
Journal:  J Clin Invest       Date:  1978-12       Impact factor: 14.808

7.  Elimination of glycosylation heterogeneity affecting heparin affinity of recombinant human antithrombin III by expression of a beta-like variant in baculovirus-infected insect cells.

Authors:  E Ersdal-Badju; A Lu; X Peng; V Picard; P Zendehrouh; B Turk; I Björk; S T Olson; S C Bock
Journal:  Biochem J       Date:  1995-08-15       Impact factor: 3.857

8.  Inhibition of thromboxane A2 synthesis in human platelets by coagulation factor Xa.

Authors:  A K Sinha; A K Rao; J Willis; R W Colman
Journal:  Proc Natl Acad Sci U S A       Date:  1983-10       Impact factor: 11.205

9.  A trypsin-like platelet protease propagates protease-activated receptor-1 cleavage and platelet activation.

Authors:  F A Ofosu; J Freedman; L Dewar; Y Song; J W Fenton
Journal:  Biochem J       Date:  1998-12-01       Impact factor: 3.857

10.  The isomorphous structures of prethrombin2, hirugen-, and PPACK-thrombin: changes accompanying activation and exosite binding to thrombin.

Authors:  J Vijayalakshmi; K P Padmanabhan; K G Mann; A Tulinsky
Journal:  Protein Sci       Date:  1994-12       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.